Home » Stocks » IART

Integra LifeSciences Holdings Corporation (IART)

Stock Price: $66.20 USD 0.29 (0.44%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 5.59B
Revenue (ttm) 1.37B
Net Income (ttm) 133.89M
Shares Out 84.65M
EPS (ttm) 1.57
PE Ratio 42.17
Forward PE 23.58
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $66.20
Previous Close $65.91
Change ($) 0.29
Change (%) 0.44%
Day's Open 66.69
Day's Range 64.95 - 66.83
Day's Volume 518,674
52-Week Range 34.21 - 71.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Forbes - 1 week ago

After the rise of 10-year yields terrified investors, the indices “reverse rotated” back into the Nasdaq and out of the Dow. Make the most of this market with today's top buys, from Q.ai's Art...

Other stocks mentioned: ATVI, LLY, NTGR, SWM
Zacks Investment Research - 1 week ago

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.

Zacks Investment Research - 2 weeks ago

Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.

GlobeNewsWire - 2 weeks ago

PRINCETON, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participati...

Zacks Investment Research - 2 weeks ago

Integra (IART) delivered earnings and revenue surprises of 13.51% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 weeks ago

Shares of Integra Lifesciences (NASDAQ:IART) moved higher by 0.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 23.53% year over y...

Benzinga - 2 weeks ago

Integra Lifesciences Holdings Corp (NASDAQ: IART) reported Q4 adjusted EPS $0.84 better than the consensus estimate of $0.73 and revenues of $388.6 million in line with expectations. Revenues ...

GlobeNewsWire - 2 weeks ago

PRINCETON, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full-year ended December...

Zacks Investment Research - 1 month ago

The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.

GlobeNewsWire - 1 month ago

PRINCETON, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previo...

Zacks Investment Research - 1 month ago

Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.

GlobeNewsWire - 1 month ago

PRINCETON, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited prel...

Zacks Investment Research - 2 months ago

Integra (IART) does not expect the selloff to have a material impact on its 2020 results.

GlobeNewsWire - 2 months ago

PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its pr...

Zacks Investment Research - 2 months ago

Integra (IART) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.

Zacks Investment Research - 2 months ago

Integra (IART) expects to close the ACell acquisition in the first quarter of 2021, subject to fulfilment of closing conditions.

GlobeNewsWire - 2 months ago

PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Peter Arduini, pr...

Seeking Alpha - 2 months ago

Integra LifeSciences is in the late stages of a transition period, rounded off by the recent divestiture of the orthopaedics segment, to be closed next year. The company has had a strong seque...

Zacks Investment Research - 2 months ago

Let's see if Integra LifeSciences (IART) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Investment Research - 3 months ago

Integra (IART) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 4 months ago

Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.

Seeking Alpha - 4 months ago

Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Integra (IART) delivered earnings and revenue surprises of 40.35% and 0.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 months ago

Shares of Integra Lifesciences (NASDAQ:IART) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 17.65% year over year to $0.80, which beat ...

GlobeNewsWire - 4 months ago

PRINCETON, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for t...

Zacks Investment Research - 4 months ago

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

IART vs. ABMD: Which Stock Is the Better Value Option?

Other stocks mentioned: ABMD
Zacks Investment Research - 4 months ago

Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.

GlobeNewsWire - 4 months ago

PRINCETON, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited prel...

Market Watch - 5 months ago

Smith & Nephew SNN, +2.16% SN, -0.91% said it's buying the extremity orthopedics unit of Integra LifeSciences IART, ...

Other stocks mentioned: SNN
GlobeNewsWire - 5 months ago

PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has entered into ...

Zacks Investment Research - 5 months ago

Integra (IART) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 6 months ago

PRINCETON, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it will part...

Zacks Investment Research - 6 months ago

Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Seeking Alpha - 6 months ago

Integra LifeSciences Holdings (IART) Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Integra (IART) delivered earnings and revenue surprises of 312.50% and 1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

PRINCETON, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for...

Benzinga - 6 months ago

On Monday, August 10, Integra Lifesciences (NASDAQ: IART) will release its latest earnings report.

Zacks Investment Research - 6 months ago

Integra LifeSciences (IART) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 7 months ago

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

First and Only Ultrasonic Tissue Ablation System Cleared to Treat Malignant and Benign Tumors, but Not Limited to Meningiomas and Gliomas First and Only Ultrasonic Tissue Ablation System Clear...

Zacks Investment Research - 7 months ago

Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.

GlobeNewsWire - 7 months ago

PRINCETON, N.J., July 09, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited pr...

Zacks Investment Research - 8 months ago

Integra (IART) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 9 months ago

PRINCETON, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced changes to its executive leadership team. Michael McBreen, who is ...

GlobeNewsWire - 9 months ago

Data Shows IBWM Reduced Operating Room Time and Costs Associated with Lower Extremity Wounds Data Shows IBWM Reduced Operating Room Time and Costs Associated with Lower Extremity Wounds

Seeking Alpha - 9 months ago

Integra Lifesciences Holdings Corp (IART) CEO Peter Arduini on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Zacks Investment Research - 9 months ago

Integra (IART) delivered earnings and revenue surprises of -20.00% and 0.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About IART

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial... [Read more...]

Industry
Medical Devices
IPO Date
Aug 16, 1995
CEO
Peter Arduini
Employees
3,700
Stock Exchange
NASDAQ
Ticker Symbol
IART
Full Company Profile

Financial Performance

In 2020, IART's revenue was $1.37 billion, a decrease of -9.60% compared to the previous year's $1.52 billion. Earnings were $133.89 million, an increase of 166.71%.

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is 70.33, which is an increase of 6.24% from the latest price.

Price Target
$70.33
(6.24% upside)
Analyst Consensus: Buy